ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $877,000 | -26.4% | 7,787 | -9.1% | 0.27% | -28.4% |
| Q4 2019 | $1,191,000 | +59.4% | 8,563 | +10.4% | 0.38% | +69.1% |
| Q3 2019 | $747,000 | -78.5% | 7,754 | -74.3% | 0.22% | -71.7% |
| Q2 2019 | $3,470,000 | -19.5% | 30,134 | -17.7% | 0.79% | -18.2% |
| Q1 2019 | $4,309,000 | +74.0% | 36,613 | -7.3% | 0.96% | +60.3% |
| Q4 2018 | $2,476,000 | -14.5% | 39,517 | -3.3% | 0.60% | +11.5% |
| Q3 2018 | $2,896,000 | +3.2% | 40,871 | -3.1% | 0.54% | -0.9% |
| Q2 2018 | $2,806,000 | -10.6% | 42,180 | -12.1% | 0.54% | -7.0% |
| Q1 2018 | $3,139,000 | +6.2% | 47,997 | -34.9% | 0.58% | -4.7% |
| Q4 2017 | $2,955,000 | – | 73,771 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |